Business Context and Reporting Period
Company: Biomerica, Inc. (BMRA)
Filing Type: Form 10-K (Annual Report)
Period Ended: May 31, 2026
Business Overview: Biomerica is a global biomedical technology company developing, manufacturing, and marketing diagnostic and therapeutic products. Key products include the inFoods® IBS diagnostic-guided therapy and the hp+detect™ test for H. pylori. The company operates manufacturing facilities in Irvine, California, and Mexicali, Mexico, with international distribution via BioEurope GmbH.
Key Financial Metrics
| Metric | Fiscal 2026 | Fiscal 2025 |
|---|---|---|
| Net Sales | $4,453,000 | $5,311,000 |
| Gross Profit | $362,000 | $498,000 |
| Gross Margin | 8.1% | 9.4% |
| Net Loss | $(3,775,000) | $(4,973,000) |
| Operating Expenses | $5,682,000 | $5,635,000 |
| Cash and Cash Equivalents (End of Period) | $1,308,000 | $2,399,000 |
| Working Capital | $1,535,000 | $3,135,000 |
| Net Cash Used in Operating Activities | $(3,421,000) | $(3,842,000) |
Debt: As of May 31, 2026, the company held a $500,000 secured promissory note payable to a related party (Chief Executive Officer) bearing 8% interest, maturing May 29, 2027.
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 16% to $4.45 million, driven by lower clinical laboratory sales, reduced over-the-counter activity due to international distributor dynamics, and the completion of a prior contract manufacturing project. These declines were partially offset by early-stage commercialization of the inFoods® IBS product.
- Expense Management: Total operating expenses increased slightly (1%) to $5.68 million. Selling, General, and Administrative (SG&A) expenses rose 6% due to higher legal and regulatory fees, while Research and Development (R&D) expenses decreased 23% as products transitioned from development to commercialization.
- Non-Operating Income: "Dividend, interest, and other income" surged 648% to $1.23 million, primarily due to a $1.1 million Employee Retention Credit (ERC) refund. Additionally, an unrealized holding gain of $335,000 was recognized on an equity investment in Diagnosis S.A.
- Liquidity: Cash and cash equivalents declined by approximately $1.09 million year-over-year, reflecting continued negative operating cash flows partially offset by financing activities.
Guidance, Outlook, Risks, and Unusual Items
Going Concern Warning
The filing explicitly states that the company's recurring losses and negative cash flows raise substantial doubt about its ability to continue as a going concern. Management believes current cash resources are insufficient to fund operations for the next twelve months without additional financing.
Outlook and Strategy
- Commercialization: Focus remains on scaling the inFoods® IBS product, which secured a $300 national Medicare payment rate effective January 1, 2026. The company is also pursuing commercial orders for hp+detect™ in the UK and Europe.
- Contract Manufacturing: Entered a Master Services Agreement in May 2026 with a target fee exceeding $1.75 million for contract development services.
- Capital Raising: The company raised approximately $1.83 million net proceeds via its At-The-Market (ATM) offering during the fiscal year. Subsequent to year-end, a private placement raised an additional $2.23 million (gross).
Key Risks
- Regulatory Compliance: Ongoing transition to EU In Vitro Diagnostic Regulation (IVDR) requirements, with deadlines for formal applications ranging from 2025 to 2027 depending on device class.
- Concentration Risk: One distributor accounted for 31% of net sales in both 2025 and 2026. Three distributors accounted for 59% of gross accounts receivable as of May 31, 2026.
- Listing Status: The company faces potential delisting from Nasdaq if its Market Value of Listed Securities (MVLS) falls below $5 million for 30 consecutive business days under new rules, though a temporary stay was in effect as of the filing date.
Investor Verification Checklist
- Capital Sufficiency: Verify the status of the post-year-end private placement ($2.23M) and the effectiveness of the ATM offering to determine if the "going concern" doubt has been resolved.
- Reimbursement Realization: Confirm actual utilization and payment rates for the inFoods® IBS product under the new $300 Medicare rate, as the filing notes that a rate does not guarantee coverage or payment.
- Distributor Concentration: Assess the financial health and order stability of the top distributor (31% of sales) and the top three receivable holders (59% of AR).
- IVDR Compliance: Monitor progress on submitting technical documentation for EU IVDR compliance to avoid market access disruptions in Europe.
- Nasdaq Listing: Track the company's Market Value of Listed Securities (MVLS) to ensure compliance with the $5 million minimum threshold.